Other Information
−Removed: During the three months ended March 31, 2026, an affiliate of the Company, Catalys Pacific Fund, LP, entered into a Rule 10b5-1 trading plan.
−Removed: Catalys Pacific Fund GP, LP is the general partner of Catalys Pacific Fund, LP.
−Removed: Brian Taylor Slingsby, M.D., Ph.D., M.P.H., one of our directors, is the managing director of Catalys Pacific, LLC, the general partner of Catalys Pacific Fund GP, LP, and has voting and investment power over the shares held by Catalys Pacific Fund, LP.
+Added: During the three months ended June 30, 2026, one of our officers (as defined in Rule 16a-1(f) of the Exchange Act) and none of our directors adopted or terminated a contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in the SEC’s rules).
The material terms of this Rule 10b5-1 trading arrangement are described below:
Name and Title
+Added: Action Taken (1)
Type of Trading Arrangement
2 unchanged sentences
Number of Securities
−Removed: Catalys Pacific Fund, LP
−Removed: Adoption January 9, 2026
−Removed: Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) Sale of the Company’s common stock pursuant to the terms of the plan May 9, 2026
−Removed: March 31, 2027
−Removed: Except as set forth above, during the three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in the SEC’s rules).
+Added: Eric Warren , Chief Commercial Officer
+Added: Adopted March 27, 2026
+Added: Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) Sale of the Company’s common stock pursuant to the terms of the plan June 23, 2026 to December 31, 2026
+Added: (1) The Rule 10b5-1 plan became effective as of April 10, 2026.
Incorporated by Reference Filed Herewith
4 unchanged sentences
8-K 2/14/23 3.2
−Removed: Non-Employee Director Compensation Policy
+Added: First Amendment to License Agreement, dated November 24, 2020 , between the Registrant and Tanabe Pharma Corporation
+Added: 10.2† Second Amendment to License Agreement, dated June 15, 2023 , between the Registrant and Tanabe Pharma Corporation
+Added: 10.3† Third Amendment to License Agreement, dated May 29, 2025 , between the Registrant and Tanabe Pharma Corporation
+Added: 10.4† Fourth Amendment to License Agreement, dated June 2, 2026 , between the Registrant and Tanabe Pharma Corporation
+Added: 10.5† L oan Agreement, dated June 2, 2026, amo ng the Registrant, Biopharma Credit PLC , BPC R Limited Partnership, and Biopharma Credit Investments V (Master) LP
31.1 Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
12 unchanged sentences
__________________
−Removed: # Indicates management contract or compensatory plan.
+Added: † Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601 of Regulation S-K because it is both not material and is the type that the registrant treats as private or confidential.
* This certification is deemed not filed for the purpose of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
1 unchanged sentence
MINERALYS THERAPEUTICS, INC.
−Removed: May 6, 2026 By:
+Added: August 11, 2026 By:
/s/ Jon Congleton
2 unchanged sentences
(Principal Executive Officer)
−Removed: May 6, 2026 By:
+Added: August 11, 2026 By:
/s/ Adam Levy
−Removed: Chief Financial Officer and Secretary
+Added: Chief Financial Officer
(Principal Financial Officer;
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.